仙琚制药：签订共同授权合作产品中国境内推广服务之三方协议及相关协议

Core Viewpoint - The collaboration between Xianju Pharmaceutical and Hangzhou Aomei Pharmaceutical focuses on the development, production, and commercialization of the drug Aomeikongsu Sodium (also known as Ageng Glucose Sodium Injection) [1][2] Group 1: Agreements and Collaborations - Xianju Pharmaceutical signed multiple agreements with Hangzhou Aomei, including the initial development cooperation agreement in December 2015, a supplementary agreement in April 2021, and a strategic cooperation framework agreement in January 2023 [1] - On January 16, 2026, Xianju Pharmaceutical, Hangzhou Aomei, and Aishijian (Guangdong) Pharmaceutical Co., Ltd. entered into a tripartite agreement to authorize Aishijian as the exclusive marketing service provider for Ageng Glucose Sodium Injection in mainland China [2] - The commercialization milestone sharing agreement and sales revenue sharing agreement stipulate that both Xianju Pharmaceutical and Hangzhou Aomei will share 50% of the commercialization milestones and net sales revenue after deducting relevant expenses [2] Group 2: Product Naming and Regulatory Aspects - The Chinese common name for Aomeikongsu Sodium and its injection form is officially recognized as Ageng Glucose Sodium and Ageng Glucose Sodium Injection, respectively [1] - The agreements outline specific terms regarding the procurement of raw materials and contract manufacturing for Ageng Glucose Sodium Injection [2]